Description
Ramatroban is a thromboxane A2 (TxA2) receptor inhibitor that exhibits anti-allergic and anti-inflammatory properties. Ramatroban also competitively inhibits chemoattractant receptor-homologous molecule on Th4 cells (CRTH2), a relatively new prostaglandin D2 (PGD2) receptor. Ramatroban decreases expression of inflammatory mediator IL-16 and also inhibits expression of adhesion molecules and prevents infiltration of immune cells.
References
Suzuki Y, Inoue T, Yamamoto A, et al. Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th4 cells antagonist ramatroban on allergic rhinitis model in mice. Biol Pharm Bull. 2011;34(4):507-10. PMID: 21467637.
Akiyama K, Karaki M, Kobayshi R, et al. IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model. Int Arch Allergy Immunol. 2009;149(4):315-22. PMID: 19295235.
Sugimoto H, Shichijo M, Okano M, et al. CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses. Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. PMID: 16256979.
Shiraishi Y, Asano K, Nakajima T, et al. Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther. 2005 Mar;312(3):954-60. PMID: 15528449.
Ishizuka T, Matsui T, Okamoto Y, et al. Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh4, a newly identified prostaglandin D2 receptor. Cardiovasc Drug Rev. 2004 Summer;22(2):71-90. PMID: 15179446.